Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > February 3, 2023
Daily News
February 3, 2023
- SCARDA to Beef Up Efforts to Discover Technologies Outside Infectious Diseases: AMED President
February 3, 2023
- Takeda Logs Double-Digit Growth, Led by Core Products and Weaker Yen
February 3, 2023
- Nobelpharma’s Nobelzin Granules Now Available, 2 Years after Approval
February 3, 2023
- Takeda Joins Pilot Study of Robotic Drug Delivery Service in Tokyo
February 3, 2023
- Roche/Chugai Drop Gantenerumab Alzheimer’s Program
February 3, 2023
- Chugai’s Sales Hit 1-Trillion-Yen Mark in 2022 on New Launches, Ronapreve
February 3, 2023
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…